Cangrelor is a novel intravenous adenosine diphosphate (ADP)-receptor antagonist with a rapid onset of action. The CHAMPION-PHOENIX trial demonstrated a reduction in the rate of ischemic events during percutaneous coronary intervention (PCI) with reduced periprocedural stent thrombosis with cangrelor administration in comparison with oral antiplatelet therapy, with no significant increase in severe bleeding. The effect of cangrelor on post-PCI residual thrombus burden has not been reported previously. We present optical coherence tomography (OCT) demonstration of the impact of cangrelor on intracoronary thrombus.